Engineered regulatory T cells could enable long-term disease remission

Regulatory T cells (Tregs) could be developed into ‘living drugs’ capable of restoring immune tolerance and treating a wide range of chronic diseases, according to a new paper [1] published in Frontiers in Science.

The authors suggest that engineered Tregs may help rebalance immune responses in conditions including type 1 diabetes, autoimmune disease, cancer, neurodegeneration, cardiovascular disease, and transplant rejection—offering a potential shift away from broad immunosuppression toward more targeted, durable control of inflammation.

Inflammation is increasingly recognised as a contributing factor in many chronic conditions, but current treatments often rely on suppressing the immune system after tissue damage has already occurred. By contrast, Treg-based therapies aim to restore immune tolerance and re-establish the body’s natural ability to regulate inflammation.

Joint lead author Dr Jeffrey Bluestone, co-founder and scientific advisor to Sonoma Biotherapeutics, said Tregs represent “some of the most exciting opportunities in modern medicine,” highlighting their potential roles beyond immune suppression, including tissue repair and metabolic regulation.

The paper also outlines how advances in genetic engineering could enable next-generation Treg therapies that are tailored to specific tissues and disease states. These approaches could allow immune responses to be precisely controlled depending on whether tolerance needs to be restored - as in autoimmunity - or selectively disrupted, as in cancer.

Early clinical studies in autoimmune disease and transplant settings have shown that Treg therapies are generally well tolerated, with initial signals of clinical benefit.

The researchers argue that the next stage of development will depend on improving precision across three areas: therapeutic design, tissue targeting and timing, and patient selection using immune profiling and biomarkers.

Co-author Professor Qizhi Tang, University of California San Francisco, said the field is moving towards replacing broad immunosuppression with “true precision tolerance.”

The authors also highlight the importance of combination strategies, including pairing Tregs with cytokines or immunomodulatory agents to enhance stability and function, alongside emerging gene engineering approaches that could improve persistence and targeting.

With continued investment and interdisciplinary collaboration, the researchers suggest that Treg-based therapies could become a new pillar of medicine alongside biologics, small molecules and gene therapies. 

More information online

1. Regulatory T cells: master orchestrators of immune tolerance and tissue homeostasis, Bluestone et al, published in Frontiers in Science